Sex-Based Differences in One-Year Outcomes After Mitral Valve Repair for Infective Endocarditis

• Published in: Revista brasileira de cirurgia cardiovascular Vol. 38; no. 5; p. e20210333
• Main Authors: Afshar, Zeinab Mohseni, Sabzi, Feridoun, Shirvani, Maria, Salehi, Nahid, Nemati, Nasim, Kheradmand, Werya, Torbati, Hadis, Rouzbahani, Mohammad
• Format: Journal Article
• Language: English; Portuguese
• Published: Brazil Sociedade Brasileira de Cirurgia Cardiovascular 01.01.2023
• Subjects: CARDIAC & CARDIOVASCULAR SYSTEMS; Cardiology; Checklist; Clinical outcomes; Diabetes; Disease; Endocarditis; Heart; Heart surgery; Hospitals; Hypertension; Medical prognosis; Mortality; Original; Patients; Reoperation; Sex; SURGERY; Treatment Outcome; Womens health; Iran; Checklist; Reoperation; Treatment Outcome; Endocarditis; Sex
• ISSN: 1678-9741; 0102-7638; 1678-9741
• DOI: 10.21470/1678-9741-2021-0333

This study was aimed to evaluate the sex-based differences in baseline characteristics and one-year outcomes of men and women undergoing mitral valve repair for infective endocarditis. This cross-sectional study was performed at Imam Ali Hospital affiliated with the Kermanshah University of Medical Science. From March 21, 2014, to October 21, 2021, all patients who underwent mitral valve repair for infective endocarditis were enrolled in this study. Data were obtained using a checklist developed based on the study's objectives. Independent samples t-tests, paired samples t-tests, and chi-squared test (or Fisher's exact test) were used to assess the differences between subgroups. Of 75 patients, 26 were women (34.7%) and 49 were men (65.3%). Women were more likely to have diabetes mellitus (20.4% vs. 57.7%, P=0.0001), hypertension (49% vs. 80.8%, P=0.007), and hypercholesterolemia (55.1% vs. 80.8%, P=0.027). Conversely, men were more likely to have a history of smoking (38.8% vs. 7.7%, P=0.004). After one year, women had significantly higher mortality (0% vs. 7.7%, P=0.049), major adverse cardiac and cerebrovascular events (51.0 vs. 76.9, P=0.029), mitral valve reoperation (8.1% vs. 34.6%, P=0.003), and treatment failure (30.6% vs. 61.5%, P=0.009) rates than men. Mortality, major adverse cardiac and cerebrovascular events, mitral valve reoperation, and treatment failure rates were higher in women than in men. The worse outcomes in women may be explained by their more adverse clinical risk profile.